Design, synthesis and SAR of novel glucokinase activators

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 7, 2013, Pages 2166-2171

  Cheruvallath, Zacharia S ^a   Gwaltney II, Stephen L ^b   Sabat, Mark ^a   Tang, Mingnam ^a   Feng, Jun ^c   Wang, Haixia ^a   Miura, Joanne ^a   Guntupalli, Prasuna ^d   Jennings, Andy ^a   Hosfield, David ^e   Lee, Bumsup ^f   Wu, Yiqin ^g  

^a Takeda San Diego Inc   (United States)

^b 400 East Jamie Court ^*  (United States)

^c Wellspring Biosciences   (United States)

^d RQX Pharmaceuticals   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Kolon Life Science Inc   (South Korea)

^g Quanticel Pharmaceuticals Inc   (United States)

Author keywords

6 Methyl pyridone; Glucokinase activator; OGTT; Structure based drug design; Type 2 diabetes

Indexed keywords

6 METHYL PYRIDONE; ANTIDIABETIC AGENT; GLUCOKINASE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; HYDROGEN BOND; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVATORS; GLUCOKINASE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; MICE, OBESE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875228325     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.01.093     Document Type: Article

References (29)

1. M. Tadayyon, and S.A. Smith Expert Opin. Invest. Drugs 12 2003 307
2. R.C. Turner, C.A. Cull, V. Frighi, and R. Holmann J. Am. Med. Assoc. 1999 2005 281
3. D.M.N. Nathan Eng. J. Med. 347 2002 1342
4. L. Gershell Nat. Rev. Drug Disc. 4 2005 367
5. D.S. Bell Treat. Endocrinol. 3 2004 67
6. F.M. Matschinsky Diabetes 51 2002 S394
7. F.M. Matschinsky, and M.A. Magnuson Frontiers in Diabetes 2004 Karger Basel 1 Vol. 16
8. A.I. Gloyn, S. Odili, D. Zelent, C. Buettger, H.A. Castleden, A.M. Steele, A. Stride, C. Shiota, M.A. Magnusson, R. Lorini, G. d'Annunzio, C.A. Stanley, J. Kwagh, E. van Schaftingen, M. Veigha da Cunha, F. Barbetti, P. Dunten, Y. Han, J. Grimsby, R. Taub, S. Ellard, A.T. Hattersley, and F.M. Matschinsky J. Biol. Chem. 280 2005 14105
9. B. Leighton, A. Atkinson, and M.P. Coghlan Biochem. Soc. Trans. 33 2005 371
10. D. Zelent, H. Najafi, S. Odili, C. Buettger, H. Weik-Collins, C. Li, N. Doliba, J. Grimsby, and F.M. Matschinsky Biochem. Soc. Trans. 33 2005 306
11. R. Sarabu, and J. Grimsby Curr. Opin. Drug Disc. Dev. 8 2005 631
12. J. Grimsby, R. Sarabu, W.L. Corbett, N.E. Haynes, F.T. Bizzarro, J.W. Coffey, K.R. Guertin, D.W. Hilliard, R.F. Kester, P.E. Mahaney, L. Marcus, L. Qi, C.L. Spence, J. Tengi, M.A. Magnuson, C.A. Chu, M.T. Dvorozniak, F.M. Matschinsky, and J.F. Grippo Science 301 2003 370
13. M.C.T. Fyfe, and M.P. Procter Drugs Future 34 2009 641
14. F.M. Matschinsky Nat. Rev. Drug Disc. 8 2009 399
15. M. Coghlan, and B. Leighton Expert Opin. Invest. Drugs 17 2008 145
16. R. Sarabu, S.J. Berthel, R.F. Kester, and J.W. Tilley Expert Opin. Ther. Patents 18 2008 759
17. 0.5 is the concentration of glucose at which the GK activity reaches half of its maximum activity.
18. K. Kamata, M. Mitsuya, T. Nishimura, J. Eiki, and Y. Nagata Structure 12 2004 429
19. Patent applications describing our GKAs have been published. Full experimental procedures for all analogs in this Letter are contained within the patent applications: (a) Cao, S. X.; Feng, J.; Gwaltney, S. L.; Hosfield, D. J.; Skene, R. J.; Stafford, J. A.; Tang, M. US200072811942.
20. Cheruvallath, Z.; Feng, J.; Guntupalli, P.; Gwaltney, S. L.; Kaldor, S. W.; Miura, J.; Sabat, M.; Tang, M. US2007213349.
21. Cheruvallath, Z.; Feng, J.; Guntupalli, P.; Gwaltney, S. L.; Miura, J.; Sabat, M.; Tang, M.; Wang, H. WO2008079787, WO2008/16107A2.
22. PDB ID code for compound 15 is 41SF, compound 22 is 41SE and compound 30 is 41SG.
23. Molecular Operating Environment (MOE), Chemical Computing Group Inc., Montreal, Canada H3A 2R7, http://www.chemcomp.com.
24. A. Reyes, I. Regla, M.C. Fragoso, L.A. Vallejo, P. Demare, H.A. Jimenez-Vazquez, Y. Ramirez, E. Juaristi, and J. Tamariz Tetrahedron 55 1999 11187
25. N. Mohamed, U. Bhatt, and G. Just Tetrahedron Lett. 1998 8213
26. N.M. Khan, M. Cano, and S. Balasubramanian Tetrahedron Lett. 2002 2439
27. Crystallographic studies with the racemic compound 30 produced a co-complex structure with only the S isomer of the compound.
28. S. Castillo, H. Ouadahi, and V. Herault Bull. Soc. Chim. Fr. 2 1982 257
29. J.C. Bressi, J. Chloe, M.T. Hough, F.S. Buchner, W. Van Voorhis, C. Verlinde, W. Hol, and M.H. Gelb J. Med. Chem. 43 2000 4135